Alembic Pharmaceuticals Limited has intimated the stock exchanges under Regulation 30 of SEBI Listing Regulations regarding the incorporation of a wholly owned subsidiary (WOS).
The company's wholly owned subsidiary, named Alembic Pharmaceuticals Global FZCO, was incorporated in Dubai, United Arab Emirates on 24th August, 2026. The company received formal intimation of this incorporation on 7th September, 2026.
Subsidiary Details:
- Name of Entity: Alembic Pharmaceuticals Global FZCO
- Date of Incorporation: 24th August, 2026
- Country of Incorporation: United Arab Emirates
- Holding Company: Alembic Pharmaceuticals Limited
- Relationship: Wholly Owned Subsidiary
- Industry: Pharmaceuticals
Business Purpose:
The subsidiary was established to explore new business opportunities and to promote, sell, and distribute pharmaceutical product(s) of Alembic Pharmaceuticals Limited.
Financial Details:
- Nature of Consideration: Cash consideration
- Cost of Subscription: AED 100,000 (Arab Emirates Dirham One Lakh Only)
- Share Subscription: 100 shares of AED 1,000 each were subscribed
- Shareholding Percentage: 100%
- Shares Allotted: 100 shares of AED 1,000 each
Regulatory Aspects:
- No governmental or regulatory approvals were required for this incorporation
- The disclosure is made in compliance with Regulation 30 of SEBI Listing Regulations, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026
- Specifically complies with Clause 1.1.A of Annexure-18 of the Master Circular
The communication was signed by Chirag K. Shukla, Company Secretary of Alembic Pharmaceuticals Limited, and addressed to both BSE Limited and National Stock Exchange of India Ltd.